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Background: This study was designed to assess whether cardiovascular magnetic resonance imaging (CMR) in
Duchenne muscular dystrophy carriers (DMDc) may index any cell milieu elements of LV dysfunction and whether
this cardiac phenotype may be related to genotype. The null hypothesis was that myocardial fibrosis, assessed by
late gadolinium enhancement (LGE), might be similarly accounted for in DMDc and gender and age-matched
controls.
Methods: Thirty DMDc patients had CMR and genotyping with 37 gender and age-matched controls. Systolic and
diastolic LV function was assessed by 2D-echocardiography.
Results: Absolute and percent LGE were higher in muscular symptomatic (sym) than asymptomatic (asy) DMDc
(1.77 ± 0.27 vs 0.76 ± 0.17 ml; F = 19.6, p < 0.0001 and 1.86 ± 0.26% vs 0.68 ± 0.17%, F = 22.1, p < 0.0001,
respectively). There was no correlation between LGE and age. LGE was seen most frequently in segments 5 and 6;
segment 5 was involved in all asy-DMDc. Subepicardial LGE predominated, compared to the mid-myocardial one
(11 out of 14 DMDc). LGE was absent in the subendocardium. No correlations were seen between genotyping
(type of mutation, gene region and protein domain), confined to the exon’s study, and cardiac phenotype.
Conclusions: A typical myocardial LGE-pattern location (LV segments 5 and 6) was a common finding in DMDc.
LGE was more frequently subepicardial plus midmyocardial in sym-DMDc, with normal LV systolic and diastolic
function. No genotype-phenothype correlation was found.
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Xp21-linked Duchenne muscular dystrophy carrier (DMDc)
status is characterized by skeletal muscle weakness ran-
ging from absence of muscular symptoms to mild or even
rapidly progressive Duchenne-like muscular dystrophy.
The muscle disease may be associated with cardiac in-
volvement, from no symptoms to overt dilated cardio-
myopathy (DCM). It is well established that a minority of
carriers is more likely to develop early severe DCM [1]
which may appear even in childhood [2]. Thus DCM may
become the only limiting factor in DMDc and the first* Correspondence: giglio.echo@libero.it
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unless otherwise stated.cause of death in these patients [3-5] whose last option for
survival is heart transplantation [6-8].
Myocardial fibrosis is best detected and quantified by
cardiovascular magnetic resonance (CMR) [9] both in
ischemic [10] and nonischemic heart diseases [11] and
may be accurately detected by late gadolinium enhance-
ment (LGE). However, LGE studies were undertaken in
DMDc quite rarely and few case reports exist [12,13].
The present study was aimed at investigating a large
consecutive series of DMDc, proven by DNA analysis and
undergoing LGE. The null hypothesis was that myocardial
fibrosis, assessed by LGE, might be similarly accounted for
in DMDc and gender and age-matched controls. We
investigated: a) the proportion of DMDc with myocardial
LGE and cardiac involvement and b) the cardiac geno-
type-phenotype relationships if any.td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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Study population
We enrolled 30 consecutive female DMDc aged 11 to
63 years (mean age 36 ± 5 years) followed at the Center
for Neuromuscular Diseases (Uildm) of Rome, Italy and
37 age-matched healthy female controls (mean age 34 ±
5 years, p = NS). Controls had no cardiac symptoms, his-
tory of cardiomyopathy or skeletal muscle disorders and
presented with normal electrocardiography (ECG), 2D-
echocardiography and CMR. No drug was given to DMDc
and controls. Creatine kinase levels were screened in the
control group and in all DMDc. The study was approved
by the Ethical Board of the Catholic University of Rome.
Written informed consent was obtained from all patients
and controls. Exclusion criteria were left ventricular (LV)
systolic and diastolic dysfunction, diabetes, hypertension,
ECG changes suggestive of ischemic heart disease, atrial
flutter/fibrillation, any degree of atrioventricular block,
valvular heart disease, and LV hypertrophy.Clinical evaluation
DMDc and controls underwent physical examination and
surface 12-lead ECG. DMDc, none with cardiac symp-
toms, were classified regarding muscle involvement as: (1)
asymptomatic (asy), when characterized by the presence
of high CK levels and/or minor myopathic signs like
muscle cramps and myalgia, without muscle weakness
and (2) symptomatic (sym), when presenting variable de-
grees of muscle weakness [14]. The degree of skeletal
muscle involvement was assessed by a neurologist and all
DMDc were divided into two functional groups: a) 21 asy
(63%) and b) 9 sym (27%). Of the 9 sym-DMDc, 3 were
mildly affected, showing some impairment in running and
jumping, 5 moderately affected, with clear strength deficits
in specific muscle districts and 1 severely affected and
wheelchair-bound. In asy-DMDc, significant coronary ar-
tery disease was excluded by negative treadmill exercise
testing. In sym-DMDc, myocardial perfusion was assessed
by adenosine thallium-201 myocardial perfusion scintig-
raphy (ATl-201-MPS), according to the guidelines for the
clinical use of cardiac radionuclide imaging [15]. ATl-201-
MPS was performed in these patients since they could not
perform treadmill exercise testing.Echocardiography
Conventional 2D-echocardiography was performed by
the same operator (VG) in all patients, using a SONOS
5500 (Philips Andover, Mass, US). LV systolic function
was assessed by ejection fraction (EF) from LV volumes
(derived using the modified Simpson’s rule). LV systolic
dysfunction was defined as LVEF ≤55%. LV diastolic
function was assessed by Doppler analysis as previously
reported [16].Dystrophin gene and protein analysis
Extensive molecular analysis was performed in all DMDc.
Mutation detection was carried out using Multiplex-
Ligation dependent Probe Amplification (MLPA) (dele-
tions and duplications) or sequencing (small mutations),
accordingly to the DMD guidelines [17]. Although muscle
biopsy may be used for establishing the carrier condition,
it is well known that approximately 60% of carriers do not
show muscle abnormalities [18].
Cardiovascular magnetic resonance
CMR was performed using a 1.5-T MR system (INTERA,
Philips Medical Systems, Best, the Netherland) with a car-
diac 5-element phased-array receiver coil . All images were
acquired with ECG-gating, breath-hold steady-state free
precession (SSFP) cine sequence for functional analysis, in
contiguous short-axis view (10-mm intervals, interslice gap
2 mm, slice thickness 8 mm in plane-resolution 1.2 ×
1.8 mm) from the mitral annulus to the apex and 3 long-
axis planes, with the patient in a supine position. To assess
the contribution of cardiac edema, we performed a T2-
weighted segmented triple inversion recovery (T2-wSTIR)
imaging module, in 3 short axis slices (8 mm, flip angle
90°, repetition times 2 RR intervals) at the base, mid, and
apex and a single long axis-slice in a 4 chamber view, using
for imaging a functional surface coil intensity correction.
All patients underwent an LGE imaging protocol (repeti-
tion time 4.5 ms, echo time 1.7 ms, inversion time 200 to
300 ms) for myocardial scar using a segmented Inversion
Recovery-Gradient Echo (IRGE) sequence, adjusting the
inversion time and nulling the signal of normal myocar-
dium. Contrast CMR images were acquired on average 10
to 15 min after injection of cumulative 0.1 mmol/kg gado-
linium DTPA (Magnevist, Gd-DTPA, Shering AG). Images
were obtained in 8 to 14 short-axis and 3 radial long-axis
planes. Myocardial enhancement on LGE images was
assessed visually and considered positive to a signal-
intensity threshold of >2 SD above the mean intensity of a
remote reference region [19] and interpreted as present or
absent by the consensus of two cardiac CMR-trained phy-
sicians. LGE quantity was quantified using manual plani-
metry, summing the LGE positive areas yielding a total
volume (ml). LGE percentage was obtained dividing the
total LGE volume by the LV mass. The LGE location and
wall motion abnormalities was classified according to
AHA for heart imaging [20]. Height and weight were mea-
sured in DMDc and controls on the day of scanning; values
for volumes and mass were indexed by body surface area
(BSA). The Simpson’s method was applied to determine
myocardial mass, end-diastolic volume, end-systolic vol-
ume, right ventricular (RV) and LV EF by a dedicated
software, manually tracing the endocardial and epicardial
borders in each short axis slice. Depressed RV and LV
systolic function were defined according to the reference
Giglio et al. Journal of Cardiovascular Magnetic Resonance 2014, 16:45 Page 3 of 7
http://jcmr-online.com/content/16/1/45values for age and gender [21]. The ventricular volumes,
RV and LV function and extent of contrast enhancement,
were analysed off-line on a dedicated workstation (Ex-
tended MR WorkSpace Release 2.6.3.2, Philips Medical
Systems, Best, the Netherland) by 2 CMR-experienced
operators blinded to clinical DMDc status.
Statistics
After testing for normal distribution based on standard
parameters, intergroup differences and relations were
compared by analysis of variance (ANOVA), correlationTable 1 Clinical data in asymptomatic and symptomatic
(from the muscular point of view) DMD carriers
Patient Age (y) Genotype CPK (UI/l)
Asymptomatic
1 57 Del ex 46-51 2750
2 21 3-17 840
3 34 Dup ex 5-6-7 1250
4 11 Del Prom + ex 1 2370
5 32 51 4000
6 30 45-52 980
7 47 3-17 1150
8 41 7-25 545
9 46 52 1745
10 37 49-50 3265
11 44 45-50 358
12 34 51 720
13 33 52 2438
14 42 Del Prom 1845
15 42 Leu 2225 Stop 3850
16 37 Dup ex 2 1645
17 44 52-54 2560
18 39 45-50 2745
19 30 51-54 650
20 38 65 3200
21 30 47-54 4250
Symptomatic
1 20 49-50 3840
2 17 48-54 5770
3 35 45-50 920
4 45 45-52 575
5 49 56 1930
6 63 48-52 4275
7 62 48-52 870
8 37 19 1600
9 45 51 2150
y = years; Del ex = Deletion exon; Dup ex = Duplication exon; Prom = Promoter;
CPK (UI/l) = Creatine kinase (normal value < 190 U/L).matrices and/or unpaired Wilcoxon t-test. NCSS software
version 2007 (www.ncss.com) was used. A value of p < 0.05
was considered statistically significant.
Results
Table 1 summarizes the clinical characteristics of the
study population. All DMDc had increased values of
serum creatine kinase that were normal in the control
group (<190 U/L). The ECG was normal in the control
group and normal or nearly normal (aspecific T-waveTable 2 LGE data in asymptomatic and symptomatic DMD
carriers
Patient LGE LGEq (ml) LGE (%)
Asymptomatic
1 - 0 0
2 - 0 0
3 - 0 0
4 - 0 0
5 + sepi 2 2
6 + mid/sepi 3 2,6
7 - 0 0
8 - 0 0
9 - 0 0
10 - 0 0
11 - 0 0
12 - 0 0
13 - 0 0
14 - 0 0
15 + mid 2 1,6
16 + sepi 2 2
17 + sepi 2 1,6
18 + sepi 2 1,6
19 + sepi 1 1
20 + mid/sepi 2 2
21 - 0 0
Symptomatic
1 + mid/sepi 1 1
2 - 0 0
3 + mid 2 2,3
4 + sepi 3 3
5 - 0 0
6 + mid 4 4
7 + mid/sepi 3 3
8 - 0 0
9 + mid/sepi 3,5 3,5
LGE = late gadolinium enhancement; LGEq (mls) = LGE quantity (milliliters);
LGE (%) = LGE percent; + = positive; − = negative; sepi = sub-epicardial;
mid = mid-myocardial.
Table 3 Clinical, and CMR data in controls and in asymptomatic versus symptomatic Duchenne carriers
Variables Controls Asymptomatic Symptomatic F p<
(n = 37) (n = 21) (n = 9)
Demographic, clinical
Age (months) 418 ± 22 441 ± 29 501 ± 44 1.4 0.25
Body surface area (m2) 1.68 ± 0.02 1.65 ± 0.03 1.63 ± 0.04 0.8 0.44
Heart rate (b/min) 78 ± 1 75 ± 1 80 ± 2 2.5 0.09
CMR
Left ventricle (LV)
Ejection fraction (%) 65 ± 1 63 ± 1 61 ± 2 2.0 0.14
End-diastolic volume (ml/m2) 106 ± 3 112 ± 4 109 ± 5 0.8 0.47
End-systolic volume (ml/m2) 37 ± 1 42 ± 2 42 ± 3 1.9 0.15
Mass (g) 108 ± 3 97 ± 4 93 ± 6(*) 4.3 0.02
Right ventricle(RV)
Ejection fraction (%) 60 ± 1 60 ± 1 61 ± 2 0.2 0.83
End-diastolic volume (ml/m2) 100 ± 3 108 ± 4 98 ± 6 1.4 0.27
End-systolic volume (ml/m2) 40 ± 2 43 ± 2 39 ± 3 0.9 0.42
DMDc = Duchenne muscular dystrophy carriers. Data are corrected by BSA and mean ± standard errors.
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independent from the LGE presence. Both treadmill
exercise testing, and ATl-201-MPS studies were negative.
CMR was performed in all DMDc and controls.
Cardiovascular magnetic resonance
Table 2 shows LGE data in asy and sym carriers: 13 asy-
DMDc were LGE negative and 8 were LGE positive. In
one young sym-DMDc (ID 1, 20 year-old) who was mo-
derately affected, subepicardial plus mid-miocardial LGE
were seen. The average RV and LV EF values were normal,
both in DMDc and controls (Table 3). No evidence ofTable 4 CMR data in controls and in asymptomatic versus sym
Variables Controls Asymptomatic
(n = 37) (n = 21)
LGE quantity (ml) 0 0.76 ± 0.17
Percent LGE versus LV mass (%) 0 0.68 ± 0.17
LGE location
Sub-endocardial 0 0
Mid-myocardial 0 0.14 ± 0.05
Sub-epicardial 0 0.33 ± 0.07
Topographic distribution
Segment 4 0 0.14 ± 0.05
Segment 5 0 0.33 ± 0.07
Segment 6 0 0.29 ± 0.07
Segment 10 0 0.05 ± 0.04
Segment 11 0 0.09 ± 0.05
Segment 12 0 0.14 ± 0.06
DMDc = Duchenne muscular dystrophy carriers. Data are mean ± standard errors.myocardial edema was seen in DMDc. LGE positive
segments were as follows: 4 basal inferior, 5 basal infero-
lateral, 6 basal antero-lateral, 10 mid inferior, 11 mid
infero-lateral and 12 mid antero-lateral. Absolute LGE
quantity was higher in sym-DMDc than asy-DMDc
(1.77 ± 0.27 vs 0.76 ± 0.17 ml, F = 19.6, p < 0.0001). LGE
percentage was also higher in sym-DMCc than in asy-
DMDc (1.86 ± 0.26 vs 0.68 ± 0.17%, F = 22.1, p < 0.0001)
(Table 4). There was no correlation between LGE presence
and age. LGE-involved LV segments were most frequently
segments 5 and 6. Segment 5 was involved in all LGE
positive DMDc. In asy-DMDc (Figure 1) and sym-DMDc,ptomatic Duchenne carriers
Between DMDc p< Symptomatic F p<
(n = 9)
0.05 1.77 ± 0.27 19.6 0.0001
0.02 1.86 ± 0.26 22.1 0.0001
- 0 -
0.02 0.56 ± 0.09 15.1 0.0001
0.57 0.44 ± 0.11 10.7 0.0001
0.08 0.44 ± 0.09 9.8 0.0002
0.09 0.67 ± 0.11 18.3 0.0001
0.05 0.67 ± 0.10 18.1 0.0001
0.15 0.22 ± 0.07 4.5 0.05
0.11 0.33 ± 0.08 6.9 0.01
0.24 0.33 ± 0.08 6.2 0.01
Figure 1 Myocardial LGE findings in asymptomatic DMDc. CMR
short-axis image of asymptomatic Duchenne carrier (ID 5, 32-year
old). Myocardial LGE was only subepicardial and confined to the
segments 5 and 6 of the inferolateral left ventricular wall.
Figure 2 Midwall fibrosis in asymptomatic DMDc. CMR short-axis
plane of asymptomatic Duchenne carrier (ID 6, 30-year old), representing
the midwall fibrosis of the inferolateral left ventricular wall. Both presented
patients (ID 5 and ID 6) had normal left ventricular function, without
regional hypokinesia in all the segments LGE-positive.
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dial one. In 5 DMDc (2 asy and 3 sym) (Table 2), LGE was
subepicardial plus midmyocardial (Figure 2). There were
statistically significant LGE distribution differences in
sym-DMDc vs asy-DMDc (Table 4): in the formers, mid-
myocardial LGE was significantly (0.56 ± 0.09 vs 14 ± 0.05,
F = 15.1, p < 0.0001) more frequent than subepicardial
LGE. Subendocardial LGE was never seen. RV was LGE
negative in all DMDc. All controls were LGE negative in
RV and LV.
Dystrophin, genomic analysis and dystrophin gene mu-
tations study. We identified 16 different exons deletions of
the dystrophin gene, two duplications and a nonsense
mutation (Table 1), in agreement with the known allelic
heterogeneity occurring in distrophinopathies [22]. All
deletions/duplications were out-of-frame, predicting pro-
tein truncations. In two DMDc (ID 4 and 14), a deletion
removing the muscle promoter region was identified,
nulling transcription of the in cis dystrophin allele. The
majority of the identified mutations were located in the
domain II spectrin-like repeats (exons 10–60, 24 patients),
clustered in the proximal rod domain, (exons 10–44, 4
patients). The exon’s study, the mutation type analysis and
the affected gene region and protein domain study, did
not show correlation between the cardiac phenotype and
genotype.
Discussion and conclusions
This is a cross-sectional study presenting a large group of
DMDc in whom, although modest in absolute and relativequantities (Table 4), we observed LGE evidence of myo-
cardial fibrosis in face of normal LV systolic and diastolic
functions. Myocardial LGE was not correlated to age and
LV function, as the only asy-DMDc with mildly reduced
LV EF had no evidence of myocardial fibrosis. LGE quan-
tity and percent were higher in sym-DMDc. Subepicardial
plus mid-myocardial LGE were more prevalent in sym-
DMDc. LGE pattern preserved the subendocardium and
was located subepicardially, at the level of basal infero-
lateral wall, most frequently distributed in segment 5
where we speculate that the fibrotic process may start.
Our study demonstrates a similar LGE distribution pat-
tern as compared to the study performed by Hor et al.
who reported an LGE prevalence of 42.7% in the LV free
wall segments of Duchenne patients [23]. Basal mid-
myocardial LGE in infero-lateral wall was observed in
Becker Xp21-linked muscular dystrophy [24]. Early CMR
in acute myocarditis, showed subepicardial or midwall
LGE [25] but our results indicate that myocardial LGE
was not a consequence of subclinical myocarditis since
myocardial edema was not found. CMR is the gold stan-
dard to evaluate the presence and location of fibrosis in
DMD affected patients [26] and may be performed even
in otherwise normal DMDc cardiac phenotype. Myo-
cardial LGE is considered a form of in vivo histologic
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increasingly being studied in DMDc, aimed at looking to
early signs of cardiac involvement and monitoring disease
progression [28,29]. LGE presence in DMDc without LV
dysfunction, might be a focal sign of heart involvement
either isolated or representing the cardiac evolution of
skeletal muscle disease. LGE may be seen in mid-myocar-
dial alone. The midwall fibrosis per se might be the result
of combined factors including abnormal cardiac energetics
and genetic factors [30]. Histopathological corroboration
of LGE-CMR abnormalities in earlier stage disease in
DMDc remains limited to absent but the advantage might
be the possibility to obtain it serially in otherwise normal
DMDc cardiac phenotype, aimed at monitoring disease
progression.
Some exons’ duplications were more frequently asso-
ciated with DCM [31]. In our study group, the only
DMDc carrying exon’s 2 duplication had subepicardial
LGE with normal LV function.
Study limitations
A major limitation of our CMR technique was that T1
mapping for measuring diffuse myocardial fibrosis [32]
was not performed. Current CMR LGE does not detect
diffuse microscopic fibrosis. We have assumed that LGE
was related to fibrosis, although no histological vali-
dation has been performed in our population. Moreover,
we did not report data on troponin T to rule out the
possible correlation between acute myocarditis and LGE.
The cross-sectional nature of this study limits its ability
to determine the precise mechanisms or rate of progres-
sion of fibrosis, because cause-and-effect cannot be de-
fined. A larger, prospectively followed-up cohort, may
give further information on additional causes of fibrosis,
its prognostic value, and its potential response to med-
ical therapy if any. In refining LV diastolic and systolic
function as causative of myocardial LGE presence, we
did not perform Tissue Doppler Imaging (TDI). In this
regard, both E/E’ ratio and Sa peak early velocity study,
in the setting of normal diastolic and systolic functions,
may not be useful in familial cardiomyopathy carriers,
before they develop full phenotype [33]. Moreover, nei-
ther were data by CMR strain and strain rate measured
which may have provided additive insight.
Clinical implications and strengths
The myocardium in DMDc is a cell milieu where LV dys-
function might be virtually present. We have shown that
LGE is frequently found, it is not correlated with age and
gene deletion type, and in absolute and relative terms it is
modest. However, subepicardial LGE is present yet at an
early age. We speculate that when LGE extends from basal
infero-lateral subepicardial level to midmyocardium, car-
diac involvement might be advanced. Presently, we ignorewhether subepicardial or midwall LGE may progress to-
wards other myocardial segments, and how long is needed
and/or whether this potential progression may in some
way influence DCM development. The association bet-
ween LGE presence and quantities and the development
of LV dysfunction while time passes, remain to be inves-
tigated. Based on the present study, the largest con-
ducted thus far, CMR may be useful in DMDc to define
the starting LV segment, an information which may not
be obtained by ECG, conventional Doppler or 2D-
echocardiography.
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